News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Pacira Pharmaceuticals, Inc. Reports 2012 Financial Results
March 7, 2013
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced consolidated 2012 financial results and provided updates on the commercial launch of EXPAREL®(bupivacaine liposome injectable suspension) for postsurgical pain in the United States.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Pacira Biosciences
MORE ON THIS TOPIC
Editorial
Eli Lilly and the LA Dodgers: A tale of 2 dynasties
October 8, 2026
·
3 min read
·
Heather McKenzie
Manufacturing
Merck barred from making subcutaneous Keytruda in 8 European countries
October 8, 2026
·
2 min read
·
Nick Paul Taylor
Drug Development
Argenx shutters Sjogren’s study, losing blockbuster expansion opportunity for Vyvgart
October 8, 2026
·
2 min read
·
Gabrielle Masson
Funding
Big Pharma–backed Matchpoint scores $150M series B, advancing autoimmune asset
October 8, 2026
·
1 min read
·
Tristan Manalac
